RxDoctor Payments Data

Sophos Geroulis, MD

Neurology · Summit, WINPI 1295820637

Payments from drug & device makers

$3,648in general payments, 2019–2025

Across 81 payments — averaging $45.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$1K
  • Genentech USA, Inc.$860
  • Biohaven Pharmaceuticals, Inc.$250
  • Jazz Pharmaceuticals Inc.$212
  • Teva Pharmaceuticals USA, Inc.$209
  • Biogen$147
  • plus $909 from 17 others

What the payments were for

  • Consulting fees$90025%
  • Speaking & faculty fees$241%
  • Food & beverage$2,61172%
  • Education$1133%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,648 in reported general payments places this provider in the 70th percentile of 308 neurology providers in Wisconsin.

See all neurology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$91,700
Medicare patients
354
Services billed
810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate67$79,179
Aimovig AutoinjectorErenumab-Aooe94$74,915
QuliptaAtogepant54$66,477
Emgality PenGalcanezumab-Gnlm45$31,970
UbrelvyUbrogepant23$31,354
Trokendi XrTopiramate17$26,050
Lacosamide84$8,996
Ajovy AutoinjectorFremanezumab-Vfrm12$8,552
Ajovy SyringeFremanezumab-Vfrm12$8,301
Carbidopa-Levodopa ErCarbidopa/Levodopa216$7,831
Levetiracetam248$6,413
Pyridostigmine Bromide ErPyridostigmine Bromide13$5,083
Zonisamide313$4,839
RivastigmineRivastigmine Tartrate89$4,711
Memantine Hcl201$4,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$80$97,83277 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$23$26,05017 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$14$2,18440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 308 neurology providers in Wisconsin.

Other neurology in Summit

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →